相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, phase 2 study
Jun Liu et al.
INTERNATIONAL JOURNAL OF CANCER (2022)
FRONTiER: A feasibility trial of nivolumab with neoadjuvant CF or DCF, FLOT therapy for locally advanced esophageal carcinoma (JCOG1804E)-Short-term results for cohorts C and D
Satoru Matsuda et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant
Ken Kato et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma
Joseph J. Zhao et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Futibatinib plus pembrolizumab in patients (pts) with advanced or metastatic urothelial carcinoma (mUC): Preliminary safety results from a phase 2 study.
Vadim S. Koshkin et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma
Y. Doki et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Toripalimab plus chemotherapy in treatment-naive, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial
Zi-Xian Wang et al.
CANCER CELL (2022)
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study
Lin Shen et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
Kohei Shitara et al.
NATURE (2022)
Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial
Zhihao Lu et al.
BMJ-BRITISH MEDICAL JOURNAL (2022)
Pembrolizumab Combined With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Locally Advanced Oesophageal Squamous Cell Carcinoma: Protocol for a Multicentre, Prospective, Randomized-Controlled, Phase III Clinical Study (Keystone-002)
Xiaobin Shang et al.
FRONTIERS IN ONCOLOGY (2022)
Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001)
Xiaobin Shang et al.
ANNALS OF TRANSLATIONAL MEDICINE (2022)
Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): Expanded efficacy and safety analyses from CheckMate 648
I. Chau et al.
ANNALS OF ONCOLOGY (2022)
RATIONALE-306: Randomized, global, placebo-controlled, double-blind phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC)
H. Yoon et al.
ANNALS OF ONCOLOGY (2022)
Association of PD-L1 Expression and OtherVariables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical Trials
Harry H. Yoon et al.
JAMA ONCOLOGY (2022)
Association of PD-L1 Expression and OtherVariables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical Trials
Harry H. Yoon et al.
JAMA ONCOLOGY (2022)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)
Chengqiang Li et al.
EUROPEAN JOURNAL OF CANCER (2021)
KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma
Manish A. Shah et al.
FUTURE ONCOLOGY (2021)
Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial
Ben M. Eyck et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
Ronan J. Kelly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial
Huiyan Luo et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth
Dennis Doleschel et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
Jong-Mu Sun et al.
LANCET (2021)
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
Yelena Y. Janjigian et al.
LANCET (2021)
Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis
Xiaoxiang Zhou et al.
LANCET ONCOLOGY (2021)
Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)
M. Moehler et al.
ANNALS OF ONCOLOGY (2020)
Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis
Abdulaali R. Almutairi et al.
FRONTIERS IN ONCOLOGY (2020)
Long-term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer
Ken Kato et al.
CANCER SCIENCE (2020)
Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E)
Shun Yamamoto et al.
FUTURE ONCOLOGY (2020)
Organ-Specific Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Monotherapy Versus Combination Therapy in Cancer: A Meta-Analysis of Randomized Controlled Trials
Lijun Da et al.
FRONTIERS IN PHARMACOLOGY (2020)
Comparative Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Advanced Cancer: A Systematic Review and Meta-Analysis
Yi Yang et al.
FRONTIERS IN PHARMACOLOGY (2020)
Treatment-Related Adverse Events of Combination Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis
Robin Park et al.
FRONTIERS IN ONCOLOGY (2020)
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
Takashi Kojima et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Aurelien Marabelle et al.
LANCET ONCOLOGY (2020)
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial
Kohei Shitara et al.
JAMA ONCOLOGY (2020)
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway
Yu Kato et al.
PLOS ONE (2019)
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials A Systematic Review and Meta-analysis
Yucai Wang et al.
JAMA ONCOLOGY (2019)
The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis
Lihu Gu et al.
BMC CANCER (2019)
Esophageal and Esophagogastric Junction Cancers, Version 2.2019
Jaffer A. Ajani et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
Ken Kato et al.
LANCET ONCOLOGY (2019)
1859PA phase II trial of preoperative chemoradiotherapy and pembrolizumab for locally advanced esophageal squamous cell carcinoma (ESCC)
S Lee et al.
ANNALS OF ONCOLOGY (2019)
Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus The Phase 2 KEYNOTE-180 Study
Manish A. Shah et al.
JAMA ONCOLOGY (2019)
A retrospective analysis of 5-fluorouracil plus cisplatin as first-line chemotherapy in the recent treatment strategy for patients with metastatic or recurrent esophageal squamous cell carcinoma
Shuji Hiramoto et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2018)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
Yelena Y. Janjigian et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The diverse functions of the PD1 inhibitory pathway
Arlene H. Sharpe et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial
Toshihiro Kudo et al.
LANCET ONCOLOGY (2017)
Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells
Zibing Wang et al.
ONCOIMMUNOLOGY (2017)
Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial
Mohan Suntharalingam et al.
JAMA ONCOLOGY (2017)
Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review
L. Khoja et al.
ANNALS OF ONCOLOGY (2017)
The epidemic of oesophageal carcinoma: Where are we now?
Aaron P. Thrift
CANCER EPIDEMIOLOGY (2016)
Update on Metastatic Gastric and Esophageal Cancers
Manish A. Shah
JOURNAL OF CLINICAL ONCOLOGY (2015)
Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy
Andrew B. Sharabi et al.
LANCET ONCOLOGY (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer
L. Bracci et al.
CELL DEATH AND DIFFERENTIATION (2014)
Mitigating the toxic effects of anticancer immunotherapy
Tara C. Gangadhar et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Esophageal Carcinoma
Anil K. Rustgi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial
Thomas Crosby et al.
LANCET ONCOLOGY (2013)
Effects of conventional therapeutic interventions on the number and function of regulatory T cells
Mario Roselli et al.
ONCOIMMUNOLOGY (2013)
A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907)
Nobutoshi Ando et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
B7-H4 expression associates with cancer progression and predicts patient's survival in human esophageal squamous cell carcinoma
Lu-jun Chen et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice
W. Joost Lesterhuis et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie
S. Lorenzen et al.
ANNALS OF ONCOLOGY (2009)
Yin-Yang of costimulation: crucial controls of immune tolerance and function
Roza I. Nurieva et al.
IMMUNOLOGICAL REVIEWS (2009)
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781
Joel Tepper et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
PD-1 and PD-1 ligands: from discovery to clinical application
Taku Okazaki et al.
INTERNATIONAL IMMUNOLOGY (2007)
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection
Arlene H. Sharpe et al.
NATURE IMMUNOLOGY (2007)
分享论文
